{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009596","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.958836+00:00","generated_at":"2026-06-17T09:08:44.234633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InspireMD Q4 revenue down 20.6% YoY; net loss widens to $4.8M; resumes CGuard shipments under MDD","bullets":["Q4 CGuard revenue $1.026M (-20.6% YoY) due to temporary CE Mark expiration; full year revenue $5.123M (+18.9%).","Net loss Q4 $4.845M ($0.60/share) vs $4.097M ($0.53) in Q4 2021; full year net loss $18.491M ($2.35/share).","Cash and equivalents $17.8M at Dec 31, 2022, down from $34.0M a year ago.","Resumed CGuard shipments to CE Mark territories in mid-March 2023 under MDD; expects MDR recertification in coming weeks.","US IDE trial enrollment on track to complete by end of Q2 2023; 20 sites currently enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009596","json":"https://secwatch.observer/filing/0001493152-23-009596.json","markdown":"https://secwatch.observer/filing/0001493152-23-009596.md","text":"https://secwatch.observer/filing/0001493152-23-009596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/0001493152-23-009596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:08:44.234633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a556208c1db12a0124b548fe2ff469f34437647","claim":"InspireMD, Inc. reported fourth quarter ended December 31, 2022 results: revenue $1,026,000, net income Net loss for the fourth quarter of 2022 totaled $4,845,000, or $0.60 per basic and diluted share, EPS $0.60 per basic and diluted share.","evidence_excerpt":"and operating results for the fourth quarter ended December 31, 2022. Fourth Quarter 2022 and Recent Developments : ● Generated CGuard revenues for the fourth quarter 2022 of $1,026,000, a 20.6% decrease from $1,291,000 for the fourth quarter of 2021. The decrease was caused by reduced shipments due to the temporary expiration of the Company’s CE Mark for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/0001493152-23-009596-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$1,026,000"},{"label":"Net income","value":"Net loss for the fourth quarter of 2022 totaled $4,845,000, or $0.60 per basic and diluted share"},{"label":"EPS","value":"$0.60 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"69869a04af7ad8c4e075aa39e892808170e68f9b","claim":"InspireMD, Inc. reported the year ended December 31, 2022 results: revenue $5,171,000.","evidence_excerpt":"For the twelve months ended December 31, 2022, total revenue increased by $676,000, or 15.0%, to $5,171,000, from $4,495,000 during the twelve months ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/0001493152-23-009596-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$5,171,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}